|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
STA-1474
Description of STA-1474:
STA-1474 is
a water soluble prodrug of ganetespib
(formerly STA-9090). STA-1474 will metabolized to Ganetespib, which is a potent HSP90 inhibitor previously shown to kill canine
tumor cell lines in vitro and inhibit tumor growth in the setting of murine xenografts. The purpose of the following study was to extend
these observations and investigate the safety and efficacy of
STA-1474 in
dogs with spontaneous tumors.
Current developer:
Synta Pharmaceuticals.
|
MedKoo Code#: 202715
|
|
Name: STA-1474
|
|
CAS#: 1118915-78-8
(STA 1474); 1118915-79-9 (STA-1474 sodium
salt)
Synonym:
Code name:
STA-1474.
IUPAC/Chemical name:
5-hydroxy-2-isopropyl-4-(4-(1-methyl-1H-indol-5-yl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl
dihydrogen phosphate
|
|
Chemical structure
|
Theoretical analysis
|
|
.gif)
|
Chemical Formula: C20H21N4O6P
Exact Mass: 444.11987
Molecular Weight: 444.38
Elemental Analysis: C, 54.06; H, 4.76; N,
12.61; O, 21.60; P, 6.97
|
|
Availability and price:
This agent is
not in stock, which may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
1: London CA, Bear MD, McCleese J, Foley KP,
Paalangara R, Inoue T, Ying W, Barsoum J. Phase I evaluation of
STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs
with spontaneous cancer. PLoS One. 2011;6(11):e27018. Epub 2011 Nov 3.
PubMed PMID: 22073242; PubMed Central PMCID: PMC3207826.
2: McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley
KP, Ying W, Barsoum J, London CA. The novel HSP90 inhibitor STA-1474
exhibits biologic activity against osteosarcoma cell lines. Int J
Cancer. 2009 Dec 15;125(12):2792-801. PubMed PMID: 19544563.
3. Cancer therapy using a combination of a heat-shock
protein 90 inhibitory compound and a topoisomerase II inhibitor By
Blackman, Ronald K.; Foley, Kevin Paul; Proia, David From PCT Int. Appl.
(2011), WO 2011149824 A1 20111201.
4. Method of treating lung adenocarcinoma with heat-shock protein 90
inhibitory compounds By Vukovi, Vojo From PCT Int. Appl. (2011), WO
2011146803 A1 20111124.
5. Cancer therapy using a combination of a heat-shock protein 90
inhibitory compound and a vascular endothelial growth factor receptor
inhibitor By Blackman, Ronald K.; Foley, Kevin P.; Proia, David From PCT
Int. Appl. (2011), WO 2011133521 A2 20111027.
6. Cancer therapy using a combination of heat-shock protein 90
inhibitory compounds and an epidermal growth factor receptor inhibitor
By Blackman, Ronald K.; Kevin, Foley P.; Proia, David From PCT Int.
Appl. (2011), WO 2011133520 A1 20111027.
7. Combination therapy using with taxanes and triazolone HSP90
inhibitory compounds for treatment of cancer By Blackman, Ronald K.;
Foley, Kevin Paul; Proia, David From PCT Int. Appl. (2011), WO
2011049946 A1 20110428.
8. Triazole compounds that modulate Hsp90 activity, and use in the
treatment of proliferative conditions By Ying, Weiwen; Sun, Lijun; Koya,
Keizo; Chimmanamada, Dinesh U.; Zhang, Shijie; Przewloka, Teresa; Li,
Hao From PCT Int. Appl. (2009), WO 2009023211 A1 20090219.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
